DNA-sequencing specialist Illumina says sales will beat diminished expectations [MarketWatch]
Illumina, Inc. (ILMN)
Last illumina, inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
illumina.com/company/investor-information.html
Company Research
Source: MarketWatch
Illumina Inc. , which specializes in genetic testing and DNA sequencing, said Tuesday afternoon that its first-quarter revenue will beat its own projections and estimates that have declined in the wake of the COVID-19 pandemic. The company said that it expects to report first-quarter revenue of about $858 million, up from $846 million a year ago and higher than the projection of $850 million to $855 million that the company provided in January. Analysts on average expected revenue of $835 million for the quarter, though that projection had declined from $857.4 million as of the end of February. Illumina did retract the rest of its guidance for this year due to uncertainty related to the spread of the coronavirus. "While our preliminary first quarter results were strong overall, we expect the second quarter to be significantly impacted by COVID-19 related disruption," Chief Financial Officer Sam Samad said in the announcement. "We are confident that this is a temporary disruption that
Show less
Read more
Impact Snapshot
Event Time:
ILMN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ILMN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ILMN alerts
High impacting Illumina, Inc. news events
Weekly update
A roundup of the hottest topics
ILMN
News
- Illumina (NASDAQ:ILMN) had its "hold (c-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Illumina (NASDAQ:ILMN) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.MarketBeat
- Illumina (NASDAQ:ILMN) was upgraded by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from a "sell (d+)" rating to a "hold (c-)" rating.MarketBeat
- Preimplantation Genetic Testing Market Size to Reach USD 1849.38 Million by 2032 – SNS Insider [Yahoo! Finance]Yahoo! Finance
- Illumina whole-genome sequencing provides greater insight into genetic signals behind common diseases--according to Nature study [Yahoo! Finance]Yahoo! Finance
ILMN
Earnings
- 10/30/25 - Beat
ILMN
Sec Filings
- 11/25/25 - Form 8-K
- 11/13/25 - Form SCHEDULE
- 11/12/25 - Form 8-K
- ILMN's page on the SEC website